MedTrace Logo

Implication of Coronary Artery Disease Burden and Pattern in Ischemia-causing Vessels With PCI

NCT04665466 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1003

Last updated 2021-04-02

No results posted yet for this study

Summary

Ischemia-guided revascularization is the cornerstone of contemporary management of coronary artery disease (CAD). Coronary physiological assessment is advocated in the catheter laboratory to guide percutaneous coronary intervention (PCI), and it is widely accepted that an FFR ≤ 0.80 is a good indicator for vessels to benefit from revascularization. Nevertheless, a significant proportion of PCI patients continue to experience adverse events related to both stented segment and/or residual or diffuse disease. Our group recently demonstrated the feasibility of pullback pressure gradient (PPG) derived from virtual Quantitative Flow Ratio (QFR) pullback curve, which is an index of atherosclerosis functional pattern and can be used to epitomize the pathophysiological pattern of CAD as focal or diffuse.

In this regard, the current study will investigate the incremental value of PPG added to QFR haemodynamic assessment in ischemia-causing vessels received PCI in predicting adverse outcomes.

Conditions

Interventions

DEVICE

Quantitative Flow Ratio derived PPG

From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as: PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2.

Sponsors & Collaborators

  • China National Center for Cardiovascular Diseases

    collaborator OTHER_GOV

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Junbo Ge, Professor · Fudan University

  • Bo Xu, MBBS · Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2021-02-28
Completion
2021-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04665466 on ClinicalTrials.gov